Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors at their meeting held on 12th November, 2025 has inter alia ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medi-Caps Limited's Board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, along with limited review report by Rawka & Associates. On a standalone basis, Q2 revenue was Rs. 99.96 lakhs (vs Rs. 97.52 lakhs in Q2 FY25), but the company swung to a loss before tax of Rs. 28.65 lakhs versus a profit of Rs. 43.54 lakhs in the year-ago quarter. Consolidated revenue from operations fell sharply to Rs. 268.76 lakhs in Q2 FY26 from Rs. 469.97 lakhs a year ago, and consolidated loss before tax widened to Rs. 182.15 lakhs. For H1 FY26, consolidated loss stood at Rs. 531.32 lakhs versus a small loss of Rs. 24.42 lakhs in H1 FY25. The wholly-owned subsidiary Medgel Private Limited alone reported a net loss after tax of Rs. 210.80 lakhs in Q2, pulling down group numbers. Basic EPS on consolidated basis turned negative at Rs. 5.26 for H1 vs Rs. 0.20 in H1 FY25.
Weak set of numbers for shareholders — consolidated revenue nearly halved year-on-year on half-year basis and the group slipped deeper into loss, mainly dragged by the loss-making subsidiary Medgel. The standalone business remains very small with no debt, but investors should watch for turnaround in the Pharma segment and the impact of Medgel on consolidated profitability.